الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 174 |  |  |
| | | from | 174 | | |
Abstract
Systemic lupus erythematosus is a heterogeneous autoimmune disease that may involve many different organs and display a variable clinical course. Despite the advances in the survival of SLE patients, the pathogenesis is still unknown yet genes play a significant role in its predisposition. SLE shows a lot of clinical presentation and has severe extra-articular manifestations and articular manifestations. It can affect any system in the body as CNS, renal, heart, lung, hematological system. It is a morbid disease and needs early diagnosis and a good follow-up to avoid complications. The activity of the disease can lead to renal failure, CNS symptoms such as fits, thrombocytopenia, pregnancy complications such as recurrent abortion in antiphospholipid syndrome and respiratory failure, and intubation and death. Treatment of SLE includes corticosteroids as the main corner of treatment and immunocompromised drugs (azathioprine, cyclophosphamide, cyclosporine), hydroquinone, and now new biological therapy as infliximab. A lot of clinical parameters and laboratory markers can be used to evaluate disease activity as Anti-dsDNA and complement serum levels which are used for evaluating disease activity. But we try to evaluate disease activity with high sensitivity with simple, available, and low-cost laboratory markers. CBC is a common test in the diagnosis and follow-up of rheumatic diseases so we can use parameters obtained from this simple test as the neutrophil- to- lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), platelet distribution width (PDW)i,and red cell distribution width (RDW). In our study, a cross-sectional comparative study that included 100 SLE patients (30 male and 70 female patients) aged from 18-55y who are recruited from the Internal Medicine Department, Rheumatology Unit (inpatient wards and outpatient clinics) the patients were classified according to the (systemic lupus erythematosus disease activity index 2000. (SLEDAI- 2K) into three groups: group (I): Inactive (SLEDAI-2K, <6) Include thirty-one patients. group (II): Moderately active (SLEDAI-2K, 6-10) Include twenty-nine patients. group (III): Highly active (SLEDAI-2k, ≥11) Include forty patients. Our study showed clinical parameters such as vasculitis, nephritis, serositis, CNS involvement are significant and indicate severe activity. Also, our study showed laboratory data as ESR, ANA, anti-dsDNA, and consumption of complement showed a significant correlation with systemic lupus activity. The highly active group had higheriPLR, NLR, PDW, and MPV than other groups. However, the highly active group showed a decrease in lymphocyte median. CNS symptoms showed a negative statistically significant correlation with lymphocytes. While it showed a positive statistically significant correlation with NLR, however, CNS showed a positive significant correlation with PDW. Nephritis had a positive significant correlation with NLR and PLR. Vasculitis had a positive highly significant correlation with lymphocytes and a positive significant correlation with PLR.